一、中文名称：Research Grade Vatreptacog alfa(DHC35901)，凝血因子VIIa类似物
二、产品描述
AnrFVIIa类似物由诺和诺德公司开发，旨在提供一种改进的旁路药物，为血友病和抑制剂患者提供更快速、可靠和持续的急性出血解决方案。考虑到减少对未充分治疗的出血的再治疗需求，减少静脉穿刺，减少疼痛和止血药物和镇痛药的消耗，以及减少对日常活动的中断，这将具有临床益处。rFVIIa类似物（以前指定为NN1731）的活性药物成分的INN名称是vatreptacog alfa（活化的），术语vatreptacog alfa被用作药物的名称。
三、产品详情
名称：Research Grade Vatreptacog alfa (DHC35901)
别名：rFVIIa analog NN1731, FVIIa DVQ, Eptacog Alfa
货号：DHC35901
表达系统：Mammalian Cells
种属反应性：Human
同种型：A recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions (Asp158Val, Val296Glu, and Glu298Met).
克隆类型：Monoclonal
靶标：F7, Proconvertin, SPCA, Serum prothrombin conversion accelerator, Coagulation factor VII, Eptacog alfa
浓度：1 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS-PAGE.
纯化方式：Purified by Nickel column.
Accession号：P08709
克隆号：Vatreptacog alfa
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
四、参考文献：
Vatreptacog alfa from conception to clinical proof of concept. PMID: 22510860
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. PMID: 22470921
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. PMID: 26362483
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. PMID: 24931322
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. PMID: 21681082
The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity. PMID: 37915568
Hemostatic properties of the FVIIa analog NN1731. PMID: 22446168
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. PMID: 31506285
Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia. PMID: 22757678
Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. PMID: 28077675
The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides. PMID: 29758051
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.antibodysystem.com/product/19169.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
